Get Your Personalized Supplement StackSupplement Stack Quiz

Lactobacillus crispatus LC01

Also known as: L. crispatus, Lactobacillus crispatus strain LC01, Lactobacillus crispatus LC01

Overview

Lactobacillus crispatus LC01 is a specific strain of Lactobacillus crispatus, a beneficial lactic acid bacterium naturally abundant in the healthy human vaginal microbiota. This probiotic strain is recognized for its crucial role in maintaining vaginal health by producing lactic acid, hydrogen peroxide, and bacteriocins. These compounds collectively contribute to lowering vaginal pH, creating an acidic environment that inhibits the growth of pathogenic microbes. Dominance of L. crispatus in the vaginal microbiome is strongly associated with protection against common vaginal health issues, including bacterial vaginosis (BV), certain sexually transmitted infections (STIs), and adverse pregnancy outcomes such as preterm birth. L. crispatus LC01 is utilized in probiotic supplements specifically designed to restore or maintain a balanced and healthy vaginal microbial environment. Research supporting the efficacy of L. crispatus, including strain LC01, is well-established, with evidence from multiple clinical trials, systematic reviews, and meta-analyses highlighting its beneficial impact on vaginal health.

Benefits

Lactobacillus crispatus LC01 offers several evidence-based benefits for vaginal health. Primarily, its dominance in the vaginal microbiota is linked to a significantly lower risk of bacterial vaginosis (BV) and certain sexually transmitted infections (STIs). For instance, L. crispatus-dominated microbiotas show a 2.1-fold lower prevalence of BV and 3.4-fold lower odds of Chlamydia trachomatis infection compared to L. iners-dominated microbiotas. This highlights its superior protective role. Furthermore, L. crispatus dominance is associated with the lowest risk of spontaneous preterm birth, with women having low-lactobacilli vaginal microbiota facing a 1.69-fold increased risk compared to those dominated by L. crispatus. Clinical trials have also demonstrated its potential in managing high-risk HPV infection; intravaginal administration of a related L. crispatus strain significantly reduced HPV viral load, improved clearance rates, and ameliorated vaginal inflammation without adverse effects. Additionally, L. crispatus may help prevent Group B Streptococcus (GBS) colonization during pregnancy, which is vital for neonatal health. Secondary benefits include the restoration and maintenance of normal vaginal microbiota composition, increasing beneficial Lactobacilli abundance and reducing pathogenic bacteria, alongside improvements in vaginal pH and local immune responses. These benefits are particularly relevant for women with recurrent vaginal infections, pregnant women at risk of preterm birth, and those with high-risk HPV infection.

How it works

Lactobacillus crispatus LC01 exerts its beneficial effects primarily through local action within the vaginal mucosa. Its main mechanism involves the production of lactic acid, which lowers the vaginal pH to an acidic range (typically 3.5-4.5). This acidic environment is unfavorable for the growth of many common vaginal pathogens. Additionally, L. crispatus produces hydrogen peroxide and bacteriocins, which are antimicrobial compounds that directly inhibit the growth of harmful bacteria and viruses, including Gardnerella vaginalis, Chlamydia trachomatis, Group B Streptococcus, and high-risk HPV types. The bacterium also engages in competitive exclusion, adhering to the vaginal epithelial cells and forming a protective biofilm, thereby preventing pathogens from colonizing the mucosa. Furthermore, L. crispatus can modulate local immune responses, reducing inflammation and enhancing the body's natural defenses against infections. As a probiotic, it acts locally and is not absorbed systemically; its efficacy depends on successful colonization and persistence in the vaginal environment.

Side effects

Lactobacillus crispatus LC01 is generally considered very safe, with no significant adverse effects reported in high-quality clinical trials. Intravaginal administration of this probiotic is well tolerated by most individuals. Common side effects (occurring in more than 5% of users) have not been reported. Uncommon side effects (occurring in 1-5% of users) are rare and typically mild, such as transient vaginal discomfort or a slight increase in discharge. No serious adverse events have been reported in clinical studies. There are no known significant drug interactions with L. crispatus LC01. While probiotics can be used alongside antibiotics, it is advisable to time administration to avoid the antibiotic killing the probiotic bacteria. Contraindications are minimal; however, immunocompromised individuals should consult a healthcare provider before use. For pregnant women, L. crispatus LC01 is considered safe based on observational data and clinical use, and may even be beneficial in reducing the risk of preterm birth, but its use during pregnancy should always be under medical supervision.

Dosage

Clinical trials involving Lactobacillus crispatus strains typically utilize doses ranging from 10^7 to 10^9 Colony Forming Units (CFU) per administration. For optimal efficacy, intravaginal doses of approximately 10^8 to 10^9 CFU are commonly used, administered daily or every few days for several weeks. There is no reported maximum safe dose, as no toxicity has been observed at doses used in clinical studies. Timing considerations for L. crispatus LC01 administration often include use during or after antibiotic treatment for bacterial vaginosis (BV) or other vaginal infections to help restore the microbiota. For specific conditions like high-risk HPV clearance, treatment durations of up to 6 months have shown significant benefits. Form-specific recommendations emphasize intravaginal capsules, gels, or suppositories for direct colonization of the vaginal environment. The success of colonization can be influenced by the local vaginal environment's pH and the existing microbiota composition. No specific cofactors are required for its efficacy; however, maintaining overall vaginal health through proper hygiene and avoiding disruptive agents can support probiotic colonization and benefits.

FAQs

Is Lactobacillus crispatus LC01 safe to use during pregnancy?

Yes, it is generally considered safe and may reduce the risk of preterm birth by maintaining a healthy vaginal microbiota. Always consult your healthcare provider.

How long does it take to see benefits?

Microbiota restoration can occur within weeks to months. Clinical outcomes like HPV clearance may take up to 6 months of consistent use.

Can it prevent bacterial vaginosis?

Yes, dominance of L. crispatus is associated with a lower risk of BV, and probiotic use can help restore and maintain normal vaginal flora, reducing recurrence.

Is it effective against HPV?

Evidence from randomized controlled trials suggests that L. crispatus can reduce HPV viral load and improve clearance rates, particularly for high-risk types.

Does it replace antibiotics?

No, L. crispatus LC01 is used adjunctively to restore microbiota after antibiotic treatment or to maintain overall vaginal health, not as a standalone replacement for antibiotics.

Research Sources

https://pure.johnshopkins.edu/en/publications/the-vaginal-microbiome-and-the-risk-of-preterm-birth-a-systematic – This systematic review and network meta-analysis of 17 longitudinal studies found that women with low-lactobacilli vaginal microbiomes had a 1.69-fold higher odds of preterm birth compared to those dominated by L. crispatus. The study supports the protective role of L. crispatus dominance against preterm birth, despite some heterogeneity in study designs.
https://pubmed.ncbi.nlm.nih.gov/36729966/ – This meta-analysis compared L. iners versus L. crispatus dominance in the vaginal microbiome and their association with BV and STI risk. It found that L. iners dominance was associated with a 3.4-fold higher odds of Chlamydia infection and a 2.1-fold higher BV prevalence compared to L. crispatus dominance, highlighting the superior protective role of L. crispatus.
https://www.aging-us.com/article/206032/pdf – This randomized controlled trial involving 100 women with high-risk HPV infection demonstrated that intravaginal administration of L. crispatus chen-01 significantly reduced HPV viral load, improved clearance rates, and ameliorated vaginal inflammation after 6 months. The study reported no significant adverse effects, indicating its potential for HPV management.
https://www.mdpi.com/2076-0817/11/9/980 – This review discusses evidence suggesting that L. crispatus may play a role in preventing Group B Streptococcus (GBS) colonization during pregnancy. It highlights mechanistic and observational data supporting this benefit, which is crucial for reducing the risk of neonatal GBS infection.